Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy

LBA8284 Background: Chemotherapy-induced anemia (CIA) often results in debilitating fatigue that can be alleviated with erythropoietic agents, epoetin alfa and darbepoetin alfa (DA). The ability to administer DA on a Q3W schedule to synchronize with the majority of chemotherapy regimens is of partic... View More